查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433330

2023-2030 年全球融合切片市場

Global Fusion Biopsy Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

預計全球融合活體組織切片市場在預測期內（2023-2030）將以 8.4% 的CAGR成長。融合活體組織切片是一種微創手術，結合磁振造影 (MRI) 和超音波技術來引導前列腺可疑區域的活體組織切片。此程序用於診斷前列腺癌，這是全世界男性最常見的癌症。市場主要參與者都致力於在市場上引入新技術，以實現更好的先進醫療和診斷。例如，2023 年 7 月，FUJIFILM Healthcare Europe 推出了 ARIETTA 65 IntuitiveFusion，這是一種具有專用前列腺融合成像功能的診斷超音波系統，可幫助泌尿科醫生簡化活體組織切片。 FUJIFILM Healthcare Europe 最近在荷蘭阿姆斯特丹舉行的歐洲泌尿外科協會 (EAU) 大會上推出了 ARIETTA 65 IntuitiveFusion。此緊湊型系統由獨特的超音波引擎和整合融合軟體提供動力，可對目標前列腺活體組織切片進行立體定向導航。

區隔市場前景

全球融合活體組織切片市場依活體組織切片途徑和最終用戶進行區隔。根據切片途徑，市場分為經直腸切片和經會陰切片檢查。根據最終用戶，市場分為醫院、診斷中心和門診護理中心。在最終用戶中，由於購買力較高，預計醫院區隔市場將佔據相當大的市場佔有率。融合活體組織切片系統的平均單價較高，私人診斷中心難以負擔。

預計經直腸區隔市場將在全球融合活體組織切片市場中佔據相當大的佔有率

在活體組織切片途徑中，經直腸子區隔市場預計將在全球融合活體組織切片市場中佔據相當大的佔有率。這種節段性生長歸因於透過直腸進行的過程。這是最常見的融合活體組織切片類型，因為它可以輕鬆進入前列腺。此外，它具有較低的感染風險和較短的手術時間，使其更適合使用。這促使該活體組織切片路線的策略性舉措增加，市場參與者正專注於開發新的和改進的產品。例如，2023 年 1 月，Bannerghatta 路的 Fortis 醫院宣布推出 BK 超音波 MRI 融合活體組織切片解決方案，改變了前列腺癌診斷和治療的遊戲規則。機器人輔助手術是一種微創手術，可以讓外科醫生在進行手術時擁有更好的視野、精確度和控制力。其他好處包括減輕疼痛、減少術後感染和減少疤痕。恢復迅速，住院時間最短，活動和復原速度更快。減少感染機會使其成為糖尿病和其他合併症患者的理想手術。

區域展望

全球融合活體組織切片市場根據地理位置進一步區隔，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於該地區前列腺癌盛行率不斷上升，預計歐洲將在全球市場中佔據顯著佔有率。根據英國前列腺癌協會的數據，平均每年有超過 52,000 名男性被診斷出患有前列腺癌，即每天有 144 名男性被診斷出患有前列腺癌。每 45 分鐘就有一名男性死於攝護腺癌，也就是說每年有超過 12,000 名男性死於攝護腺癌。

北美地區全球融合活體組織切片市場預計將以顯著的CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於新產品的推出、現有業務的擴張、前列腺癌意識的提高、人口基數的增加以及該地區可支配收入水準的提高。根據美國國家癌症研究所的數據，每年每 10 萬名男性中有 113.4 例前列腺癌新病例。每年每 10 萬名男性中有 18.8 人死亡。根據 2017-2019 年的資料，大約 12.9% 的男性將在一生中的某個時刻被診斷出患有前列腺癌。 2020 年，美國估計有 3,343,976 名男性罹患攝護腺癌。因此，市場參與者不斷在該地區推出用於癌症治療的新產品。例如，2023 年 6 月，Hoag 推出了 Focal One（一種非侵入性機器人高強度聚焦超音波 (HIFU) 技術），為患有局限性前列腺癌的男性提供了一種與疾病作鬥爭的額外治療選擇。 HIFU 是一種精確針對癌性前列腺組織的先進技術，使泌尿科醫生能夠僅消融或破壞前列腺的患病部分。結果是癌症治療沒有治療整個前列腺所帶來的許多副作用，包括泌尿和勃起副作用。

市場參與者展望

服務於融合活體組織切片市場的主要公司包括 Eigen Health、ESAOTE SpA、Focal Healthcare、GeoScan Medical、Hitachi Ltd.、KOELIS、Koninklijke Philips NV、MedCom、UC-Care Medical Systems Ltd. 等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2022 年 8 月，Promaxo, Inc. 宣布已與歐洲領先的大學醫院、倫敦帝國學院和德國圖賓根大學醫院開展 MR 引導前列腺干預研究合作。 Promaxo 與倫敦帝國學院合作，獲得了一筆資助並簽訂了一項臨床研究協議，該研究比較 Promaxo 的攜帶式 MRI 和 TRUS-Fusion 活體組織切片，以評估前列腺癌檢測的準確性。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個區隔市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 在全球融合活體組織切片市場中運作的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵區隔市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 依區隔
    • 依地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • ESAOTE SpA
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Koninklijke Philips NV
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • UC-Care Medical Systems Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場區隔

  • 依活體組織切片路線分類的全球融合活體組織切片市場
    • 經直腸
    • 經會陰
  • 依最終用途分類的全球融合活體組織切片市場
    • 醫院
    • 診斷中心
    • 門診護理中心

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Eigen Health
  • Focal Healthcare
  • GeoScan Medical
  • Hitachi Ltd.
  • innoMedicus Ltd
  • KOELIS
  • MEDCOM Sp. z o. o
Product Code: OMR2028004

Global Fusion biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal and Transperineal), and by End User (Hospitals, Diagnostic Centers and Ambulatory Care Centers), Forecast Period (2023-2030)

The global fusion biopsy market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). Fusion biopsy is a minimally invasive procedure that uses a combination of magnetic resonance imaging (MRI) and ultrasound technology to guide the biopsy of suspicious areas in the prostate gland. This procedure is used to diagnose prostate cancer, which is the most common cancer among men worldwide. The major players in the market are focusing on introducing new technology in the market for better advanced medical treatment and diagnosis. For instance, in July 2023, FUJIFILM Healthcare Europe unveiled the ARIETTA 65 IntuitiveFusion, a diagnostic ultrasound system with dedicated prostate fusion imaging to help urologists streamline biopsies. FUJIFILM Healthcare Europe launched the ARIETTA 65 IntuitiveFusion at the recent European Association of Urology (EAU) congress in Amsterdam, the Netherlands. This compact system is powered by ultrasound unique engine and integrated fusion software to allow stereotactic navigation of targeted prostate biopsies.

Segmental Outlook

The global fusion biopsy market is segmented on the biopsy route, and end user. Based on the biopsy route, the market is sub-segmented into transrectal and transperineal. Based on the end user, the market is sub-segmented into hospitals, diagnostic centers and ambulatory care centers. Among the end-user, the hospital sub-segment is anticipated to hold a considerable share of the market, owing to high purchasing power. The average unit price of a fusion biopsy system is high, making it unaffordable for private diagnostic centers.

The Transrectal Sub-Segment is Anticipated to Hold a Considerable Share of the Global Fusion biopsy Market

Among the biopsy route, the transrectal sub-segment is expected to hold a considerable share of the global Fusion biopsy market. This segmental growth is attributed to factor includes, the process performed through the rectum. This is the most common type of fusion biopsy, as it allows for easy access to the prostate gland. Also, it has lower risk of infection and shorter procedure time which make it more suitable to use. It lead to increase in strategic initiatives for this Biopsy Route and market players are focusing on developing new and improved products. For instance, in January 2023, Fortis Hospital, Bannerghatta Road announced the launch of BK ultrasound MRI Fusion Biopsy solution, a game changer in Prostate cancer diagnosis and treatment. Robot-aided surgery is a minimally invasive procedure which allows surgeons to have better vision, precision, and control while performing the surgeries. Other benefits include decreased pain, fewer post-operative infections and less scarring. Recovery is rapid, with minimal hospital stay, faster mobilization and rehabilitation. Reducing the chance of infection makes it an ideal procedure for people with diabetes and other co-morbidities.

Regional Outlook

The global fusion biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to rising prevalence of prostate cancer in the region. According to Prostate Cancer UK, more than 52,000 men are diagnosed with prostate cancer every year on average - that is 144 men every day. Every 45 minutes one man dies from prostate cancer - that is more than 12,000 men every year.

The North America Region is Expected to Grow at a Significant CAGR in the Global Fusion biopsy Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to new product launches, expansion of already existing business, rising awareness of prostate cancer, increasing population base, and rising disposable income levels in the region. According to National Cancer Institute, the rate of new cases of prostate cancer was 113.4 per 100,000 men per year. The death rate was 18.8 per 100,000 men per year. Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2017- 2019 data. In 2020, there were an estimated 3,343,976 men living with prostate cancer in the United States. Hence, the market players are continuously introducing new product for cancer treatment in the region. For instance, in June 2023, Hoag is giving men with localized prostate cancer an additional treatment option in the battle against disease with the introduction of Focal One, a non-invasive robotic High Intensity Focused Ultrasound (HIFU) technology. An advanced technology that precisely targets cancerous prostate tissue, HIFU allows urologic surgeons to ablate, or destroy, just the diseased portion of the prostate. The result is a cancer treatment without many of the side effects that come with treating the entire prostate, including urinary and erectile side effects.

Market Players Outlook

The major companies serving the fusion biopsy market include Eigen Health, ESAOTE SpA, Focal Healthcare, GeoScan Medical, Hitachi Ltd., KOELIS, Koninklijke Philips N.V., MedCom, UC-Care Medical Systems Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2022, Promaxo, Inc. announced it has entered into research collaborations with leading European university hospitals, Imperial College London and University Hospital Tuebingen Germany, for MR guided prostate interventions. In collaboration with Imperial College London, Promaxo received a grant and entered into a research agreement for a clinical study comparing Promaxo's portable MRI and TRUS-Fusion biopsy to assess for accuracy in prostate cancer detection.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global fusion biopsy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. ESAOTE SpA
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Koninklijke Philips N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. UC-Care Medical Systems Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Fusion biopsy Market by Biopsy Route
    • 4.1.1. Transrectal
    • 4.1.2. Transperineal
  • 4.2. Global Fusion biopsy Market by End-use
    • 4.2.1. Hospitals
    • 4.2.2. Diagnostic Centers
    • 4.2.3. Ambulatory Care Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Eigen Health
  • 6.2. Focal Healthcare
  • 6.3. GeoScan Medical
  • 6.4. Hitachi Ltd.
  • 6.5. innoMedicus Ltd
  • 6.6. KOELIS
  • 6.7. MEDCOM Sp. z o. o

LIST OF TABLES

  • 1. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 4. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 12. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 13. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 14. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 15. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 18. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FUSION BIOPSY MARKET SHARE BY BIOPSY ROUTE, 2022 VS 2030 (%)
  • 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL FUSION BIOPSY MARKET SHARE BY END-USE, 2022 VS 2030 (%)
  • 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. US FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 10. CANADA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. UK FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. FRANCE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. GERMANY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. ITALY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. SPAIN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. REST OF EUROPE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. INDIA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CHINA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. JAPAN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. SOUTH KOREA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF ASIA-PACIFIC FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF THE WORLD FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)